Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Healthy young hearts sharper older minds make
Roberts, Rosebud O., Knopman, David S.

Annals of Neurology | January 29, 2013 | Volume: 73 | Issue: 2 | Pages: 151-152

10.1002/ana.23847 | PMID 23526555 Get It

Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience
Azambuja, Evandro de , Bradbury, Ian , Saini, Kamal S. , Simon, Sérgio D. , Dooren, Veerle Van, Aktan, Gursel, Wolff, Antonio C. , Jackisch, Christian , Láng, István, Boyle, Frances , Baselga, José , Perez, Edith A. , Piccart, Martine , Metzger, Otto , Bines, José , Pritchard, Kathleen I. , Smith, Ian , Untch, Michael , Xu, Binghe , Wolff, Antonio C , de Azambuja, Evandro

The Oncologist | January 29, 2013 | Volume: 18 | Issue: 2 | Pages: 134-140

10.1634/theoncologist.2012-0342 | PMID 23359433 Get It

Abstract Learning Objectives Discuss methods for improving the efficiency of global clinical trials. Explain the need for national regulatory authorities and collaborative cancer groups to initiate efforts to quicken the activation process in their countries. Describe the activation process of phase III studies and its complex and heterogeneous regulation across different geographic and economic regions. Purpose. This study measured the time taken for setting up the different facets of Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO), an international phase III study being conducted in 44 participating countries. Methods. Time to regulatory authority (RA) approval, time to ethics committee/institutional review board (EC/IRB) approval, time from study approval by EC/IRB to first randomized patient, and time from first to last randomized patient were prospectively collected in the ALTTO study. Analyses were conducted by grouping countries into either geographic regions or economic classes as per the World Bank's criteria. Results. South America had a significantly longer time to RA approval (median: 236 days, range: 21–257 days) than Europe (median: 52 days, range: 0–151 days), North America (median: 26 days, range: 22–30 days), and Asia-Pacific (median: 62 days, range: 37–75 days). Upper-middle economies had longer times to RA approval (median: 123 days, range: 21–257 days) than high-income (median: 47 days, range: 0–112 days) and lower-middle income economies (median: 57 days, range: 37–62 days). No significant difference was observed for time to EC/IRB approval across the studied regions (median: 59 days, range 0–174 days). Overall, the median time from EC/IRB approval to first recruited patient was 169 days (range: 26–412 days). Conclusion. This study highlights the long time intervals required to activate a global phase III trial. Collaborative research groups, pharmaceutical industry sponsors, and regulatory authorities should analyze the current system and enter into dialogue for optimizing local policies. This would enable faster access of patients to innovative therapies and enhance the efficiency of clinical research.
Evaluation of Treatment Benefit in Journal of Clinical Oncology
Goodwin, Pamela J. , Cannistra, Stephen A., Ballman, Karla V. , Small, Eric J.

Journal of Clinical Oncology | January 29, 2013 | Volume: 31 | Issue: 9 | Pages: 1123-1124

10.1200/jco.2012.47.6952 | PMID 23358984 Get It

Single-Use Instrumentation, Cutting Blocks, and Trials Decrease Contamination during Total Knee Arthroplasty: A Prospective Comparison of Navigated and Nonnavigated Cases
Johnson, Aaron J. , Issa, Kimona , Pivec, Robert, Blasser, Kurt, McQueen, David A., Puri, Lalit , Dethmers, Daniel A., Miller, David B. , Ireland, Philip H. , Shurman, John R, Bonutti, Petter, Mont, Michael A.

Journal of Knee Surgery | January 29, 2013 | Volume: 26 | Issue: 04 | Pages: 285-290

10.1055/s-0033-1333664 | PMID 23359398 Get It

Emerging Subspecialties in Neurology: Deep brain stimulation and electrical neuro-network modulation
Hassan, Anhar , Okun, Michael S. , Okun, Michael S

Neurology | January 29, 2013 | Volume: 80 | Issue: 5 | Pages: No page available

10.1212/wnl.0b013e31827f0f91 | PMID 23359377 Get It

Views of Recently First-Certified US Child Neurologists on Their Residency Training
Gilbert, Donald L. , Patterson, Marc C. , Pugh, John, Ridel, Keith R., Reynolds, Thomas Q., Valencia, Ignacio , Patterson, Marc

Journal of Child Neurology | January 28, 2013 | Volume: 28 | Issue: 3 | Pages: 332-339

10.1177/0883073812473644 | PMID 23358629 Get It

We surveyed child neurologists first certified in “Neurology with Special Qualification in Child Neurology” by the American Board of Psychiatry and Neurology (ABPN) between 2001 and 2010 using a 24-item questionnaire. Respondents (n = 204, 54% response rate) were between the ages of 30 and 59 years (54% male), and 68% completed adult neurology training in a 10- to 12-month, primarily inpatient block. Sixty-two percent of the sample completed subspecialty fellowship training and 82% currently reported practicing within a hospital or hospital-based/owned clinic. Current practice data showed just 3% provide general neurology services to adults. A majority reported using adult neurology residency training “less than weekly” and believed the ideal model for residency training in diagnosis and management of both common and rare neurologic conditions would involve less time in adult neurology and more time (mean 6 months) in child neurology, most prominently in genetics and developmental and behavioral areas.
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Goss, Paul E., Budd, G. Thomas , Rabaglio, Manuela , Ansari, Rafat , Johnson, David B. , Tozer, Richard , D’Souza, David , Chalchal, Haji , Spadafora, Silvana , Stearns, Vered , Perez, Edith A. , Liedke, Pedro Emanuel Rubini , Láng, István, Elliott, Catherine, Chapman, Judy-Anne W., Shepherd, Lois E. , Ingle, James N. , Pritchard, Kathleen I. , Ellis, Matthew J. , Sledge, George W. , Gelmon, Karen A. , Chapman, Judy‐Anne W., Stearns, Vered , Rabaglio-Poretti, Manuela

Journal of Clinical Oncology | January 28, 2013 | Volume: 31 | Issue: 11 | Pages: 1398-1404

10.1200/jco.2012.44.7805 | PMID 23358971 Get It

Purpose In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non–cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. Patients and Methods We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease–free survival, incidence of contralateral new primary breast cancer, and safety. Results In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease–free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. Conclusion This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor–positive breast cancer.
Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
Ferwana, Mazen, Firwana, Belal , Hasan, Rim, Al‐Mallah, Mouaz H. , Kim, S., Montori, Víctor M. , Murad, M. Hassan , Murad, M Hassan , Montori, Victor M , Al-Mallah, Mouaz H

Diabetic Medicine | January 28, 2013 | Volume: 30 | Issue: 9 | Pages: 1026-1032

10.1111/dme.12144 | PMID 23350856 Get It

AbstractAimsPioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta‐analysis to evaluate the magnitude of this association and the quality of the supporting evidence.MethodsElectronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer.ResultsSix studies involving 215 142 patients using pioglitazone were included, with a median period of follow‐up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09–1.39; I2 = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years.ConclusionsPatients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti‐hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.
Symptomatic internal carotid artery medialization: A rare anatomic variant resulting in cough, dysphonia, and dysphagia
Abel, Kathryn M. Van , Carlson, Matthew L. , Moore, Eric J. , Van Abel, Kathryn M

Clinical Anatomy | January 28, 2013 | Volume: 26 | Issue: 8 | Pages: 966-970

10.1002/ca.22178 | PMID 23355276 Get It

Hydrogel‐PLGA delivery system prolongs 2‐methoxyestradiol‐mediated anti‐tumor effects in osteosarcoma cells
Maran, Avudaiappan , Dadsetan, Mahrokh, Buenz, Colleen M., Shogren, Kristen L., Lu, Lichun , Yaszemski, Michael J.

Journal of Biomedical Materials Research Part A | January 28, 2013 | Volume: 101A | Issue: 9 | Pages: 2491-2499

10.1002/jbm.a.34550 | PMID 23355512 Get It

Osteosarcoma is a bone tumor that affects children and young adults. 2‐Methoxyestradiol (2‐ME), a naturally occurring estrogen metabolite, kills osteosarcoma cells, but does not affect normal osteoblasts. In order to effectively target osteosarcoma and improve the therapeutic index of the drug 2‐ME, we have encapsulated 2‐ME in a composite of oligo‐(polyethylene glycol) fumarate (OPF) hydrogel and poly (lactic‐co‐glycolic acid) (PLGA) microspheres and investigated the effect of polymer composition on 2‐ME release kinetics and osteosarcoma cell survival. The in vitro study shows that 2‐ME can be released in a controlled manner over 21‐days. The initial burst releases observed on day 1 were 50% and 32% for OPF and OPF/PLGA composites, respectively. The extended release kinetics show that 100% of the encapsulated 2‐ME is released by day 12 from OPF, whereas the OPF/PLGA composites showed a release of 85% on day 21. 2‐ME released from the polymers was biologically active and blocked osteosarcoma cell proliferation in vitro. Also, comparison of 2‐ME delivery in osteosarcoma cells in culture, shows that direct treatment has no effect after 3 days, whereas polymer‐mediated delivery produces anti‐tumor effects that could be sustained for 21 days. These findings show that the OPF and PLGA polymeric system may prove to be useful in controlled and sustained delivery of 2‐ME and could be further explored in the treatment of osteosarcoma. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 101A: 2491–2499, 2013.